Potential Research Participants
  • For more information about a specific study, please call the contact person listed for that study.
  • For general questions about participating in research studies at OHSU you may contact the Clinical Research Navigator at (503) 346-3540.
  • If you have any questions regarding your rights as a research subject, you may contact the OHSU Research Integrity Office at (503) 494-7887.

 
Return to Search

 
Study Opportunities (376 Results)
 
1) A Phase II Study of Patients with Newly Diagnosed Primary Central Nervous System Lymphoma Treated with Methotrexate/BBBD, and Adding Rituximab (an anti CD-20 Antibody) and Carboplatin, to the Treatment Regimen
2) Mechanism of Retinal Damage in Autoimmune Retinopathy
3) Neurocognition and Brain Development in Youth (Attention Deficit)
4) Phase I/II Study of Carboplatin, Melphalan and Etoposide Phosphate in Conjunction with Osmotic Opening of the Blood-Brain Barrier and Delayed Intravenous Sodium Thiosulfate Chemoprotection, in Previously Treated Subjects with Anaplastic Oligodendroglioma or Oligoastrocytoma
5) Oregon Colorectal Cancer Registry
6) MRI Protocol Development and Optimization
7) Oregon Pancreas Tissue Registry
8) Quantitative Dynamic Contrast-Enhanced Breast MRI
9) [UMiami – MOU] TrialNet Natural History Study of the Development of Type 1 Diabetes
10) Phase I/II Study of Intra-arterial Melphalan Given with Intra-arterial Carboplatin, Osmotic Blood-Brain Barrier Disruption and Delayed Otoprotective Sodium Thiosulfate for Patients with Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
11) Preclinical studies on endometrial xenografts
12) Oregon Liver Tumor Registry
13) Transepithelial Potential Difference Measurements in Patients with Unusual Variants of Cystic Fibrosis
14) VAPORHCS/OHSU J:Optimization of Cochlear Implants and Hearing Aids
15) I-SPY 2 TRIAL: Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2
16) Harold Schnitzer Diabetes Health Center Research Department Contact and Health Information Repository
17) Objective grading of intraocular inflammation in uveitis using optical coherence tomography
18) Relationship between HLA B27, disease status and the human microbiome
19) Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies
20) Disorders of Water and Electrolyte Balance
21) Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) Acute Myeloid Leukemia (AML).
22) Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)
23) A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
24) Oregon Index of Endocrine Neoplasias (ORION)
25) The Use of Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE MRI) in the Management of Pancreatic Cancer
26) Longitudinal observational study using functional and structural optical coherence tomography to diagnose and guide treatment of glaucoma
27) A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma
28) A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
29) S1203: A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
30) Circadian rhythms and cardiovascular risk
31) VAPORHCS/OHSU J: Identifying the Determinants of Long-Term Type Specific Immunity in a Dengue Immune Cohort
32) CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia (CASCADE FH Registry)
33) A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-Lag-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas
34) A pilot study for the Varicella Zoster Vaccine (VERVE) Trial
35) SARC024: A blanket protocol to study oral regorafenib in patients with selected sarcoma subtypes
36) Optical coherence tomography angiography in neovascular age-related macular degeneration
37) A Phase I, Multicenter, Open-Label Study of Oral ABL001 in Patients with Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
38) War on Melanoma: Enlisting a cohort of melanoma survivors and their families
39) Immune Dysregulation in HIV-Infected Adults with Substance Abuse and the Impact of Addiction
40) A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed after First-Line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
41) OCTRI Research Volunteer Registry
42) Urinary Microbiomes: Do they play a role in Urgency Urinary Incontinence?
43) [NCI CIRB]S1400: Lung-MAP, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
44) A Phase II Multicenter Randomized Trial Evaluating 3-Year Disease-Free Survival in Patients with Locally Advanced Rectal Cancer Treated with Chemoradiation Plus Induction or Consolidation Chemotherapy, and Total Mesorectal Excision or Non-Operative Management
45) VAPORHCS/OHSU J: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (VA/OHSU (J): CREST-2)
46) Phase 2 Study of Preoperative Chemotherapy with Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic Cancer
47) Role of Fatty Acid Oxidation Defects in Insulin Sensitivity
48) Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide (MDV3100) in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy
49) A Phase 1/2 Proof-of-concept study of the combination of ACP-196 and ACP-319 in subjects with B-cell malignancies
50) Developing A Smart Predictor App for AAC Conversation
51) [STEM CELLS] Germline Gene Therapy of Inherited Diseases
52) Developing a National Registry for JORRP (Juvenile Onset Recurrent Respiratory Papillomatosis)
53) Alzheimer's Comprehensive Treatment Network of Oregon and Washington (ACTNOW)
54) Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
55) A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
56) A Phase III, Open-Label Randomized Study of Atezolizumab (Anti-PD-LI Antibody) Compared with A Platinum Agent (Cisplatin or Carboplatin) in Combination with either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naïve Patients with Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
57) VAPORHCS/OHSU J: Buspirone, in combination with amantadine, for the treatment of levodopa-induced dyskinesia (VA MIRB 3753)
58) Protocol CCTL019B2206: A multicenter study of apheresis collection of peripheral blood mononuclear cells (PBMC) in patients with CD19 expressing malignancies who could be eligible for a CTL019 clinical research trial
59) Sarcoma Survivorship Registry
60) Melanoma Tissue Bank Consortium: A Multi-Center Repository of Biospecimens and Data for Future Use
61) A Phase 1B Dose Escalation and Dose Expansion Study of ONO/GS-4059 in Combination with Other Targeted Anti-cancer Therapies in Subjects with B-cell Malignancies
62) VAPORHCS/OHSU J: Measuring Cortisol Levels in Persons with Parkinson's (PD)
63) An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
64) A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies
65) VAPORHCS/OHSU J: Efficient diagnostic tools to evaluate central auditory dysfunction
66) A Phase 3 Prospective, Randomized, Double-Blind, Multi-Center, Study Of The Efficacy And Safety Of Lanreotide Autogel/ Depot 120mg Plus BSC Vs Placebo Plus BSC For Tumor Control In Subjects With Well-Differentiated, Metastatic And/Or Unresectable Typical Or Atypical Lung Neuroendocrine Tumors
67) Automatic Voice-Based Assessment of Language Abilities
68) IIT: A Phase II study of Obinutuzumab (GA-101) in Combination with Ibrutinib (I) for the Treatment of Relapsed Mantle Cell Lymphoma (ML29535)
69) Prosody Assessment Toolbox
70) CC #144525: Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
71) A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile
72) Human blood collection to support research assay development
73) Attention, Emotion, and Neurophysiology across Development
74) A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
75) Serial Measurements of Molecular and Architectural Responses to Therapy
76) Oregon SPARK: National Autism Cohort 50k
77) A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versusPlacebo in Subjects with High Risk Invasive Urothelial Carcinoma
78) A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
79) CA209-451: A Randomized, Multicenter, Double Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (SCLC) after Completion of Platinum-based First Line Chemotherapy
80) Clofazimine in the treatment of pulmonary Mycobacterium avium complex (MAC) disease
81) The OHSU Pancreas Community Registry
82) Knight Cardiovascular Institute Aortic Disease Registry
83) (ONC-DPX-Survivac-06): A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac with Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients with Recurrent Ovarian Cancer
84) The Efficacy of Topical Silver Nitrate Versus Cryotherapy in the Treatment of Common Warts
85) Internet-based Conversational Engagement Clinical Trial
86) A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
87) Feasibility of Medical Abortion by direct-to-consumer telemedicine
88) [NCI CIRB] The National Myelodysplastic Syndromes (MDS) Study
89) A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLE BLIND STUDY OF SELINEXOR (KPT-330) VERSUS PLACEBO IN PATIENTS WITH ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS)
90) A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC-402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients with Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
91) A Phase II study of induction systemic mFOLFIRINOX followed by hepatic arterial infusion of Floxuridine and Dexamethasone given concurrently with systemic mFOLFIRI as a first-line therapy in patients with unresectable liver-dominant intrahepatic cholangiocarcinoma
92) Response Assessment to Pembrolizumab with Standard of Care Therapy in Glioblastoma Using Ferumoxytol Steady State Imaging– A Pilot Study
93) A Phase 1B Study of Ribociclib in Combination with Doxorubicin in Advanced Soft Tissue Sarcomas
94) Molecular Mechanisms of Tumor Evolution and Resistance to Therapy
95) VAPORHCS/OHSU J: The brain-behavior relationship: age, hearing, and their effects on understanding speech in noise
96) A Phase 1 Non-Randomized, Open-Label/Phase 2 Randomized, Blinded Study of ProTmune (ex vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects with Hematologic Malignancies
97) Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta
98) A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in combination with Ipilimumab placebo Squamous Cell Carcinoma of the Head and Neck (SCCHN)
99) Improving the effectiveness of orally-dosed emergency contraceptives in obese women
100) Phase 1b Safety and Tolerability Study of ZEN003694 in Combination with Enzalutamide or Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer (ZEN003694-002)
101) [Advarra – IAA] CINC280A2201: A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC)
102) A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
103) VAPORHCS/OHSU J: The use of repetitive transmagnetic stimulation to target craving in methamphetamine use disorder (MIRB 3856)
104) AAV8-mediated Low Density Lipoprotein Receptor (LDLR) Gene Replacement in Subjects with Homozygous Familial Hypercholesterolemia (HoFH)
105) A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations
106) A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission
107) A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
108) Targeting CD200 with Samalizumab to Enhance Outcomes in Elderly Untreated Core-Binding Factor Acute Myeloid Leukemia
109) Phase 1b/2 Study of BI 836858 with Azacitidine in Previously Untreate AML Patients >60 Years With Unique Molecular Features
110) A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma
111) REMOTE DATA SENSING TO CONSTRUCT DIGITAL BIOMARKERS ASSOCIATED WITH DISEASE PROGRESSION IN MCI AND AD: A PROOF OF CONCEPT STUDY IN PATIENTS UTILIZING SYMPTOMATIC AD THERAPIES
112) Substance-Induced Changes in Neurocircuitry in 21 year olds
113) A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY
114) A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma
115) Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation
116) A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination with Nivolumab in Subjects with Selected Advanced Solid Tumors
117) The use of perfusion MRI using ferumoxytol and small molecular weight gadolinium (Gd) agents to assess response to pembrolizumab in brain metastases and systemic lesions in NSCLC: A comparison of imaging modalities to address brain metastases, pseudoprogression and systemic lesion tumor flare (neuro-check pilot)
118) (TESARO 4010-01-001) A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
119) [NCI CIRB] A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
120) A Phase 1B Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination with Azacitidine in Subjects with Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
121) A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy
122) A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma
123) Wide-field and Projection-Resolved Optical Coherence Tomography Angiography in Diabetic Retinopathy
124) Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
125) A Phase II Study to Assess the Efficacy of the Treatment of IDH2 Mutant AML with Targeted IDH2 Inhibition and Subsequent Response-Driven Addition of Hypomethylating Agent Therapy
126) A Phase 1b/2 Study of Entospletinib (ENTO) in Patients with Acute Myeloid Leukemia (AML) > Age 60 with MLL gene rearrangements and/or MLL-Partial Tandem Duplications (MLL-PTD)
127) A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation
128) A Phase I Study of Donor BPX-501 T Cell Infusion for Adults with Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
129) A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination with Azacitidine in Subjects with Relapsed/Refractory Myelodysplastic Syndromes
130) IIT Phase I Study of pevonedistat (MLN4924, TAK924) in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and non-Hodgkin lymphoma
131) A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)
132) Zoster Eye Disease Study (ZEDS): A multi-center, randomized, double-masked, placebo-controlled study of valacyclovir in immunocompetent subjects with a history of dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and/or iritis due to Herpes Zoster Ophthalmicus (HZO) within the year prior to enrollment.
133) A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
134) DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study
135) [18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer
136) VAPORHCS/OHSU J: Brain Training For Central Auditory Dysfunction After Traumatic Brain Injury
137) A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
138) A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy and Pharmacokinetics in Patients with Advanced Malignancies
139) A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared with CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
140) VAPORHCS/OHSU J: Evaluation of a Spasticity Management Program for People with Multiple Sclerosis
141) Transcatheter Aortic Valve Replacement to Unload the Left Ventricle in Patients with Advanced Heart Failure: A Randomized Trial (TAVR UNLOAD)
142) An open-label, parallel-group, randomized, multicenter study to assess the safety and efficacy of Vilaprisan in subjects with uterine fibroids versus standard of care
143) VHAPORHCS/OHSU J: STAT-PD: Preventing Levodopa Induced Dyskinesia in Parkinson's disease with HMG-CoA Reductase Inhibitors (MIRB # 3869)
144) VAPORHCS/OHSU J:Neurobiology of Alcohol and Nicotine Co-Addiction
145) VAPORHCS/OHSU J:Rehabilitation of Complex TBI with Sensory Integration Balance Deficits; Can Early Initiation of Rehabilitation with Wearable Sensor Technology Improve Outcomes?
146) Phase 1b, multi-arm, open-label study of PDR001 and/or MBG453 in combination with decitabine in patients with acute myeloid leukemia or high risk myelodysplastic syndrome
147) VAPORHCS/OHSU J:Photosensitivity and Pain in Complex Traumatic Brain Injury
148) A Phase 3, Multi-Center, Open-Label Randomized Study of Oral Asciminib Versus Bosutinib in Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated with 2 or more Tyrosine Kinase Inhibitors
149) The effect of intervention for vocal fold immobility (VFI) on cough effectiveness
150) [NCI CIRB] A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
151) Circadian Mechanisms of Cardiovascular Risk in Obesity
152) MonarchE: Protocol 13Y-MC-JPCF A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
153) A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination with Navitoclax and Chemotherapy in Subjects with Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
154) A Phase 2 Study of Entospletinib and Decitabine Targeting Mutant TP53 and or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia > Age 60 years
155) A Phase 2 Study of Entospletinib in NPM1 mutant/FLT3 ITD Wild Type AML Patients Age > 60 years
156) A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial
157) A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma
158) A Phase 2 open-label study of the CSF1R inhibitor JNJ-40346527 in patients with relapsed/refractory acute myeloid leukemia (AML)
159) Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma
160) A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML
161) A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma
162) VAPORHCS/OHSU J: Isolation and analysis of circulating tumor cells (CTCs) and nucleic acids from patient blood specimens
163) A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers
164) CA209-816 - Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
165) A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
166) Trans(Intra)-arterial Gemcitabine vs. Continuation of IV Gemcitabine and Nab-Paclitaxel following Radiotherapy for Locally Advanced Pancreatic Cancer
167) A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
168) A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma
169) TRITON3: A Multicenter, Randomized, Open-Label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer Associated with Homologous Recombination Deficiency (protocol CO-338-063)
170) A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
171) Feasibility of assessing drug response to precise local injection of anti-cancer drugs using Presage’s CIVO™ device in soft tissue sarcoma patients undergoing surgery.
172) Phase 2 Study Comparing Efficacy and Safety of ABT-165 plus FOLFIRI vs Bevacizumab plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab
173) A pharmacokinetic study of Centella asiatica product (CAP) in elderly participants with mild cognitive impairment receiving cholinesterase inhibitor therapy
174) Exercising Together: A randomized controlled trial of partnered exercise training on the health of couples coping with cancer
175) Prophylactic Tumor Treating Fields in Management of Patients with Small Cell Lung Cancer
176) CCN012B: A multicenter, open-label randomized study on the efficacy, cycle control and safety of a contraceptive vaginal ring delivering a daily dose of Nestorone® and estradiol (NES-E2 CVR)
177) Effect of tetrahydrocannabinol (THC) on sleep in humans
178) A Phase I/II, open-label, multi-center study evaluating the safety and efficacy of Ruxolitinib and CPX-351 in combination for the treatment of Secondary Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms.
179) [JAEB IRB] Myopia Treatment Study 1
180) [NCI CIRB] S1609, "DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS”
181) Phase 2 Study with Pevonedistat in combination with Azacitidine targeting NEDD8-activating enzyme (NAE) in TP53 Mutant Untreated Acute Myeloid Leukemia patients ≥ 60 years of age
182) Modular phase 2 study to link combination immune-therapy to patients with advanced solid and hematologic malignancies Module 9: PDR001 plus LAG525 for patients with advanced solid and hematologic malignancies
183) A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma
184) A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF BA3011 IN PATIENTS WITH ADVANCED SOLID TUMORS
185) A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
186) A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy
187) A PHASE 1/2 STUDY OF ORAL LOXO-292 IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING RET FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION (LIBRETTO-001)
188) [WIRB – MOU ADRN] Effect of Dupilumab (anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
189) A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacamten (MYK-461) in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction
190) Peptide Biomarkers for Alzheimer Disease
191) Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
192) Phase I Study to Evaluate Safety of Ruxolitinib in Combination with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia
193) An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
194) A Phase 1, Open-label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies or Acute Myeloid Leukemia After Failure of Prior Standard Therapies
195) Teen Musculoskeletal Pain Outcomes (TEMPO)
196) A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients with Hypertriglyceridemia and Established Cardiovascular Disease (CVD) or at High Risk for CVD
197) [NCI CIRB] A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
198) A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
199) Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
200) A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
201) A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
202) A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
203) Group Exercise Training for Fall Prevention and Functional Improvements During and After Treatment for Prostate Cancer
204) An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
205) Monoclonal antibody-based sequential therapy for deep remission in multiple myeloma – MASTER trial
206) [NCI CIRB] S1702, A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis
207) Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia
208) [Washington University IRB - SMART IRB] Chronic Venous Thrombosis: Relief with Adjunctive Catheter-Directed Therapy
209) An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
210) Phase 2 Study of AG-120 combined with Azacitidine in Previously Untreated AML Patients > 60 Years with an IDH1 Mutation
211) A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects with High-Risk, Transplant-Eligible, Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (TRANSFORM)
212) MODERATE – Monitoring dementia-related agitation using technology evaluation
213) A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF BA3021 IN PATIENTS WITH ADVANCED SOLID TUMORS
214) VAPORHCS/OHSU J: Validation of Walking Aid Use Metrics in People with Multiple Sclerosis Using an Innovative, New Device: HoldTrak
215) A Phase II, Open Label, Study of Olaparib and Durvalumab in Patients with Metastatic Triple Negative Breast Cancer
216) Delivering Early Intervention to Children with Down Syndrome Through Telemedicine
217) [WIRB - IAA] Gilteritinib Monotherapy or in Combination with Decitabine in Elderly Untreated FLT3 mutated Acute Myeloid Leukemia With High and Low Variant Allele Frequency (VAF)
218) VHAPORHCS/OHSU J: Ataxia in Essential Tremor: Describing the differences betweendisease process and treatment effect (ATAX)
219) A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
220) Early Feasibility Study of the Edwards Transcatheter Atrial Shunt System
221) A Phase I Study of PI3Kα,δ Inhibitor Copanlisib in Combination with PD-1 Antagonist Nivolumab in Patients with Transformed Chronic Lymphocytic Leukemia (Richter’s Transformation) or Non-Hodgkin Lymphoma
222) A phase III, randomized, double-blind study of chemotherapy with daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation plus midostaurin (PKC412) or chemotherapy plus placebo in newly diagnosed patients with FLT-3 mutation negative acute myeloid leukemia (AML)
223) A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
224) Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin (Mylotarg) in Combination with Cytarabine, Anthracycline and Midostaurin Induction for Patients with Newly Diagnosed FLT3 Positive Acute Myeloid Leukemia (AML)
225) Neuro-correlates of motor fatigue in MS
226) [Advarra-IAA] A Randomized, double-blind, placebo controlled study to evaluate efficacy and safety of nefecon in patients with primary IgA nephropathy at risk of progressing to End-Stage renal disease (NefIgArd)
227) A Phase 3, Randomized, Double-blind, Active Comparator controlled, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Recipients of Allogeneic Hematopoietic Stem Cell Transplant (PNEU-STEM)
228) MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX)
229) The Impact of Pediatric Skin Disorders: The "Big" Study.
230) Validating a Cell Culture for studying cervical mucus and measuring copper levels in mucus.
231) A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients with Hematologic Malignancies
232) A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects with Epilepsy with a Predictable Seizure Pattern
233) Comparison of two- versus three-antibiotic therapy for pulmonary Mycobacterium avium complex disease
234) A Phase II, single arm, multicenter open label trial to determine the efficacy and safety of tisagenlecleucel (CTL019) in adult patients with refractory or relapsed follicular lymphoma
235) A phase 1 study of FOR46 administered every 21 days in patients with metastatic castration-resistant prostate cancer (mCRPC)
236) A Phase II Trial of Perioperative CV301 Vaccination in Combination with Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer
237) An Open-Label, Phase 2 Trial to Investigate the Humoral and Cell-Mediated Immune Responses and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Flavivirus-Naïve and Dengue-Immune Healthy Adults
238) A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA
239) Transcatheter Aortic Valve Replacement (TAVR) with Medtronic TAVR System in Patients with Severe Bicuspid Aortic Valve Stenosis and at Low Predicted Risk of Mortality with Surgical Aortic Valve Replacement (SAVR)
240) A Phase II study of Xisomab 3G3, a monoclonal antibody preventing the activation of FXI by FXIIa, for the prophylaxis of PICC line-associated thrombosis.
241) Mechanisms of Action of MBCT-PD: A Pilot Study
242) A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer
243) [Advarra IAA]- A phase 3, multi-center, open-label study of a levonorgestrel 52 MG intrauterine system for the treatment of heavy menstrual bleeding
244) VAPORHC/OHSUJ: Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis
245) VAPORHCS/OHSU J: HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function
246) [NCI CIRB] EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
247) [NCI CIRB] S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
248) A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
249) STUDY OF DURVALUMAB OR DURVALUMAB AND TREMELIMUMAB AS MAINTENANCE TREATMENT FOR PATIENTS WITH LIMITED STAGE SMALL-CELL LUNG CANCER WHO HAVE NOT PROGRESSED FOLLOWING CONCURRENT CHEMORADIATION THERAPY (ADRIATIC)
250) [NCI CIRB] NRG-BN003: A Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
251) SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity
252) An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post– ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor
253) A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera
254) A Targeted approach to examine the influence of maternal psychological stress on newborn brain outcomes
255) [WIRB – MOU ADRN] ADRN-06 Integrated Extreme Trait Analysis to Understand the Etiology of Eczema Herpeticum Etiology of EH
256) Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma (LEAP-002)
257) A Prospective Multicenter Open-Label Randomized Controlled Trial of Agili-C vs. Surgical Standard of Care (SSOC) for the Treatment of Joint Surface Lesions of the Knee
258) The effect of a sub-symptom threshold aerobic exercise program on recovery in concussed athletes
259) A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED TRIAL OF DS-8201A, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC), VERSUS TREATMENT OF PHYSICIAN’S CHOICE FOR HER2LOW, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS
260) [Advarra - SMART IRB] A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of GRF6021 Infusions in Subjects with Parkinson’s Disease and Cognitive Impairment
261) A Feasibility Study to Assess a Window of Opportunity Strategy for Targeted PARP or MEK Inhibition in Patients with Pancreatic Ductal Adenocarcinoma
262) [NCI CIRB] A041501 - A Phase III Trial To Evaluate the Efficacy Of The Addition Of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) To Frontline Therapy In Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell All
263) Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing
264) A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib (INTRIGUE)
265) A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
266) A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
267) A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
268) A Phase 1b Dose-escalation Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
269) A randomized, multicenter, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer
270) Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
271) The STELLA Collaborative:Using Technology to Advance ADRD Family Education and Support
272) A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
273) Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub-Clinical Atrial fibrillation (ARTESiA)
274) [MCW IRB-CML MOU] Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients who Relapsed After a Prior Attempt at TKI Discontinuation
275) A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)
276) A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2A STUDY TO ASSESS THE EFFICACY AND SAFETY OF REGN3500 MONOTHERAPY AND COMBINATION OF REGN3500 PLUS DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
277) Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥ 60 years) with Relapsed/Refractory Acute Myeloid Leukemia (AML)
278) An open label pilot trial of guselkumab in the treatment of adults with Pityriasis Rubra Pilaris (PRP)
279) Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicenter Trial (EMERALD)
280) A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects with Disability Following an Ischemic Stroke (PISCES III)
281) A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects with Hematological Malignancies
282) Aging Well with Independence using Sensors in the Environment
283) An open-label, multi-institutional phase 0 study to assess the use of glucarpidase in patients with osteosarcoma receiving high-dose methotrexate
284) A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
285) A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose- Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176
286) A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
287) Electronic Financial Indicators of Neurodegenerative Disease
288) A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)
289) SPYRAL HTN-ON MED
290) VAPORHCS/OHSU J: Improving sleep, sleep-related outcomes, and biomarkers in Veterans
291) PHASE 2 ACTIVE TREATMENT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SRK-015 IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY (TOPAZ)
292) [NCI CIRB] LUNGMAP - A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer
293) Differentiating High Myopia from Glaucoma Using Functional and Structural Optical Coherence Tomography
294) A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
295) [Quorum Review - SMART IRB] A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure
296) A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
297) [NCI CIRB] S1900A - A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRAC1/2 Mutation Stage IV or Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub Study)
298) A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
299) A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT® FOR ATOPIC DERMATITIS (R668-AD-1762)
300) An Open label, Phase I/II study to evaluate the safety and efficacy of Tenalisib (RP6530), a novel PI3K δ/γ dual inhibitor, given in combination with a histone deacetylase (HDAC) inhibitor, Romidepsin in adult patients with relapsed/refractory T-cell Lymphoma
301) Phase 1b Study to Assess the Safety of Neoadjuvant TAS-102 (triFluridine/tIpiracil) with ConcurrEnt Radiation in Previously Untreated Resectable Stage II and Stage III ReCtal CancEr (FIERCE)
302) [Advarra - SMART IRB] A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD˗9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
303) Randomized, Open-label, Active-controlled Study to Assess the Safety, Tolerability and Efficacy of Afabicin IV/oral in the Treatment of Patients with Bone or Joint Infection due to Staphylococcus
304) A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas
305) [NCI CIRB] S1802: Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
306) [NCI CIRB] EA8143 (PROSPER): A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy
307) An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis
308) A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
309) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies
310) ADJUVANT THERAPY WITH PEMBROLIZUMAB VERSUS PLACEBO IN RESECTED HIGHRISK STAGE II MELANOMA: A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY (KEYNOTE 716)
311) An Open-Label Study with Extension Phase to Evaluate the Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Subjects (Age 1 Month to Less Than 18 Years) With Childhood Epilepsy
312) A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)
313) [NCI CIRB] EA9161 - A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
314) An International, Phase 3, Multicenter, Randomized, Open-Label Trial Comparing Balixafortide in combination with Eribulin versus Eribulin alone in Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer
315) A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma
316) A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9–Engineered T Cells (CTX110) in Subjects with Relapsed or Refractory B-Cell Malignancies
317) [NMDP - BMT CTN MOU] A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (Mi-Immune)
318) [WIRB - IAA] A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
319) A Phase 3 Randomized, Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza infection in Immunocompromised Subjects
320) [NCI CIRB] - A041702 - A RANDOMIZED PHASE III STUDY OF IBRUTINIB PLUS OBINUTUZUMAB VERSUS IBRUTINIB PLUS VENETOCLAX AND OBINUTUZUMAB IN UNTREATED OLDER PATIENTS (≥ 70 YEARS OF AGE) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
321) [NCI CIRB] - S1712 - A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease
322) [WIRB - IAA] WATCH-PD (Wearable Assessments in the Clinic and Home in PD)
323) A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF APREMILAST (CC- 10004) IN SUBJECTS WITH MODERATE TO SEVERE GENITAL PSORIASIS
324) [NCI CIRB] EA6174: A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
325) A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer
326) A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF EQ001 IN SUBJECTS WITH NEWLY DIAGNOSED ACUTE GRAFT VERSUS HOST DISEASE
327) [Advarra IRB- IAA] A Phase 3 multicenter, randomized, double-blind, placebo controlled,clinical study to assess the efficacy and safety of linzagolix in subjects with moderate to severe endometriosis-associated pain.
328) A Phase II, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects with Palmoplantar Pustulosis
329) [NMDP - BMT CTN MOU] 1702: Clinical Transplant Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D)
330) [VUMC - IREx] The Impact of Low Flow Nocturnal Oxygen Therapy on Hospital Admissions and Mortality in Patients with Heart Failure and Central Sleep Apnea (LOFT-HF)
331) [NMDP - BMT CTN MOU] CTN 1704: Composite Health Assessment Model for Older Adults: Applying Pre-Transplant Comorbidity, Geriatric Assessment, and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplantation (CHARM)
332) A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED MELANOMA
333) Early detection of hereditary transthyretin amyloid polyneuropathy using in-vivo reflectance confocal microscopy of Meissner's corpuscles
334) Disabled Nursing Faculty Study
335) [NCI CIRB] A031704 - PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
336) [NCI CIRB] MATCH - EAY131 - Molecular Analysis for Therapy Choice (MATCH)
337) [NCI CIRB] - EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
338) Delivering Enhanced Milieu Teaching Via Telehealth to Children and Families in Rural Communities
339) Early Access Program (EAP) for avapritinib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
340) Comparison of GI transit times in levodopa-responders and non-responders in patients with Parkinson's disease
341) A Randomized Controlled Trial to Assess the Effectiveness of Virtual Reality in Education for Cancer Patients Undergoing Radiation Therapy
342) A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy.
343) A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions
344) [NCI CIRB] EA2165 - A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
345) [NCI CIRB] S1800A - A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care For Patients Previously Treated With Immunotherapy For Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Non-Matched Sub-Study)
346) A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease
347) Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination with Ado-trastuzumab Emtansine (T-DM1) for Subjects with Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer
348) A phase 3, multi-center, randomized, open-label, assessor-blind stay to evaluate the efficacy and safety of Mino-Lok Therapy (MLT) in combination with systemic antibiotics in the treatment of catheter-related or central line-associated bloodstream infection.
349) Evaluating the effects of resistance and aerobic exercise on glucose and lipids in pregnant women with gestational diabetes
350) A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
351) Using Optical Coherence Tomography Angiography to Capture Dynamic Retinal Vascular Changes in Demyelinating Disease
352) VAPORHCS/OHSU J: A Randomized Controlled Trial of a Multicomponent Walking Aid Program for People with MS
353) A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis, BEAT-MS
354) [NCI CIRB] A031702 - A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
355) [NCI CIRB] S1803: PHASE III STUDY OF DARATUMUMAB/rHuPH20 (NSC- 810307) + LENALIDOMIDE OR LENALIDOMIDE AS POST-AUTOLOGOUS STEM CELL TRANSPLANT MAINTENANCE THERAPY IN PATIENTS WITH MULTIPLE MYELOMA (MM) USING MINIMAL RESIDUAL DISEASE TO DIRECT THERAPY DURATION (DRAMMATIC STUDY)
356) ORCASTRAIT Oregon Roybal Center for CAre Support Translational Research Advantaged by Integrating Technology
357) A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)
358) [IntegReview IRB - IAA] A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy
359) VAPORHCS/OHSU J: MitoQ for fatigue in multiple sclerosis: a placebo controlled trial
360) Cerebellar transcranial magnetic stimulation for motor control in progressive supranuclear palsy
361) Cerebrospinal Fluid Dynamics in Older Adults with and without Mild Cognitive Impairment
362) [NCI CIRB] A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
363) Clinical Effectiveness of Conventional Versus Mirasol-treated Apheresis Platelets in Patients with Hypoproliferative Thrombocytopenia (MIPLATE)
364) [MOU - NMDP IRB] An Open-Label, Single-Arm, Multicenter Study, of Combination anti-CD3/CD7 Immunotoxin (T-Guard) for Steroid-Refractory Acute Graft-versus-Host Disease
365) Diet, Microbiome and Interval Breast Cancer Study
366) Sedentary Behavior, Cardiovascular Function, and Sleep
367) [NCI CIRB] S1826 - A PHASE III, RANDOMIZED STUDY OF NIVOLUMAB (OPDIVO) PLUS AVD OR BRENTUXIMAB VEDOTIN (ADCETRIS) PLUS AVD IN PATIENTS (AGE >/= 12 YEARS) WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA
368) A Randomized Trial of Standard Verbal Counseling with or without a Pictorial Educational Tool to Reduce Psychological Morbidity in Women Receiving Breast Radiation Therapy
369) Disparities and Barriers to Care for Gender Non-conforming Patients with Epilepsy and Spells: A longitudinal study - PSU MOU- Build Exito
370) DCC-2618-99-001: Expanded Access Program for Ripretinib in Patients with Locally Advanced Unresectable or Metastatic GIST Who Have Received Treatment with Prior Therapies
371) A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)
372) Development of a Machine Learning Model for Prostate Cancer Treatment Planning
373) [NCI CIRB] EA4181 - A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients
374) Characteristics Associated with Communicative Participation after Total Laryngectomy
375) A Phase I study to evaluate the pharmacokinetic and pharmacodynamic profile of intramuscular or subcutaneous injections of levonorgestrel butanoate (LB) for female contraception
376) [NCI CIRB] A051701 - Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Return to Search